FDA-cleared profile

Salix Coronary Plaque (V1.0.0)

Artrya Limited

Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Salix Coronary Plaque (V1.0.0) is a web-based adjunctive tool for qualified cardiologists and radiologists to quantify and characterize coronary plaque and stenosis and perform calcium scoring from adult cardiac CT DICOM images.
FDA source Exact FDA submission Checked 2026-09-07
Intended users
Qualified cardiologists and radiologists reviewing adult cardiac CT; the software is an adjunct and does not replace professional judgment.
FDA source Exact FDA submission Checked 2026-09-07
Care setting and population
Adult cardiac CT/CCTA interpretation in cardiology or radiology practice.
FDA source Exact FDA submission Checked 2026-09-07
Workflow role
Post-processing and quantitative coronary plaque, stenosis, and calcium assessment to support physician review of cardiac CT findings.
FDA source Exact FDA submission Checked 2026-09-07
Required input
Adult CCTA or non-contrast calcium-scoring cardiac CT DICOM images acquired on a CT scanner.
FDA source Exact FDA submission Checked 2026-09-07
Output and human action
Total, calcified, non-calcified, low-density non-calcified, and plaque-burden measurements; CAD-RADS stenosis grade; vessel and lumen profiles; calcium score; vessel centerlines, labels, and segmentations; and a coronary analysis report.
FDA source Exact FDA submission Checked 2026-09-07
Limitations
The software is adjunctive and interpolated views may appear normal for lesions at or below image resolution. Automated outputs and interpolated views require qualified clinical review; the FDA evidence is regulatory technical validation rather than independent clinical-outcome evidence.
FDA source Exact FDA submission Checked 2026-09-07

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251837
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-07
Anatomy
Heart/Cardiovascular
FDA source Exact FDA submission Checked 2026-09-07
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-08-20
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The exact submission accepts cardiac CT DICOM images and operates through a secured network server with image storage; site-specific PACS/RIS routing, identifiers, and report delivery require acceptance testing.
FDA source Exact FDA submission Checked 2026-09-07
Deployment and data flow
The FDA packet describes a web-based application with secured network-server integration and image storage; it does not establish the site hosting topology, retention, availability, or managed-service boundary for the exact release.
FDA source Exact FDA submission Checked 2026-09-07
Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

The reviewed exact packet and Artrya family indication page do not establish current scoped security controls, certification scope, PHI flow, retention, access control, audit, or incident response for K251837.

Training and support
Use requires qualified cardiologist or radiologist review of plaque, stenosis, calcium, and segmentation outputs; local onboarding should cover image eligibility, editing, interpolated-view limitations, reports, and escalation.
FDA source Exact FDA submission Checked 2026-09-07
Monitoring and change control
Monitor eligible CT series, segmentation and plaque edits, stenosis and calcium report completeness, failed or repeated analyses, PACS delivery, reader overrides, downtime, updates, complaints, and recalls by exact K251837 release.
FDA source Exact FDA submission Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and validation scope; it is not a claimed vendor monitoring service.

Secured cardiac CT server workflow

The exact submission describes a web-based application accepting adult cardiac CT DICOM images through secured network-server integration with image storage; validate local PACS routing and identity mapping before use.

exact submission · checked 2026-09-07

Artrya Salix family workflow

Artrya's current Salix indication describes a web-based tool for trained professionals that supports cardiac CT plaque, stenosis, and calcium scoring on CT data from any CT scanner as an adjunct to clinical judgment.

product family · checked 2026-09-07

Current family indication; confirm exact K251837 version, scanner compatibility, hosting, licensing, and local interfaces.

Report and segmentation acceptance

Buyer acceptance should test vessel labeling, centerline and wall segmentation edits, plaque composition outputs, CAD-RADS reporting, non-contrast calcium workflow, and behavior near image-resolution limits.

exact submission · checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K251837 FDA evidence is a seven-center regulatory validation of Salix Coronary Plaque V1.0.0 outputs; no independent paper or trial was promoted in this timeboxed review.
FDA source Exact FDA submission Checked 2026-09-07
Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Vessel-level stenosis within one CAD-RADS category

95.8 percent

Agreement with reference stenosis category within one CAD-RADS category in 103 adult patients from seven geographically diverse U.S. centers.

Tested version: Salix Coronary Plaque Software Application V1.0.0

Total plaque volume ICC

0.96 ICC

Agreement of total plaque volume with reference in Adult cardiac CT validation cases.

Tested version: Salix Coronary Plaque Software Application V1.0.0

Centerline overlap

0.8604 overlap coefficient

Agreement of extracted coronary centerline with reference in Adult cardiac CT validation cases.

Tested version: Salix Coronary Plaque Software Application V1.0.0

K251837 Salix Coronary Plaque regulatory validation

Retrospective multi-center regulatory validation of coronary plaque, stenosis, calcium, segmentation, and labeling outputs against reference annotations. · 103 adult patients from seven geographically diverse U.S. centers; 302 non-contrast and 107 contrast series were reported across task-specific analyses.

exact submission · Tested version: Salix Coronary Plaque Software Application V1.0.0 · n=103 · 7 sites · Sponsor or vendor study

K251837

Manufacturer-submitted FDA evidence; it is not an independent clinical-outcome study.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

No public list price or contract unit for the exact K251837 configuration was established in the reviewed official sources.

Reimbursement and coding
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
Public source Product family Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251837 or establish individual claim eligibility.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251837. This does not establish absence of family, later-version, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-07

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-07.

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and...

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28